AI Summary Alpha1-proteinase inhibitor therapy is dosed at 60 mg/kg by weekly IV infusion for severe AATD with emphysema, but it is not indicated for AATD-related liver disease.
Medically reviewed.
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder caused by mutations in the SERPINA1 gene. In its classic form, people carry two copies of the "Z" allele (Pi*ZZ), which causes an abnormal AAT protein to build up inside liver cells instead of being secreted normally, leading to liver injury. AATD can also affect the lungs, where a lack of circulating AAT protein leaves lung tissue vulnerable to damage from neutrophil elastase, often causing emphysema.
Alpha1-proteinase inhibitor (A1-PI) augmentation therapy — Prolastin-C, Glassia, Aralast NP, and Zemaira — is the therapy used for AATD. These plasma-derived medications replace the missing AAT protein to protect the lungs. This page explains how A1-PI therapy works, who may benefit, and why it is not a treatment for AATD-related liver disease. You can also connect with a liver specialist to discuss how to manage AATD-related liver disease.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ALPHA-1 ANTITRYPSIN DEFICIENCY THERAPY OVERVIEW
Alpha1-proteinase inhibitor (A1-PI) augmentation therapy includes plasma-derived medications — Prolastin-C, Glassia, Aralast NP, and Zemaira — used to treat adults with severe Alpha-1 Antitrypsin Deficiency (AATD) and clinically significant emphysema.
These therapies replace the missing or deficient alpha1-proteinase inhibitor protein in the bloodstream, helping protect lung tissue from ongoing damage caused by neutrophil elastase. Treatment is typically long-term, often lifelong, and given as a weekly intravenous infusion.
All four A1-PI products are dosed the same way — 60 mg/kg by intravenous infusion once weekly — and work by replacing the deficient alpha1-proteinase inhibitor protein to inhibit neutrophil elastase and slow the decline in lung function associated with AATD.
Explore this therapy:
Healthcare providers may prescribe A1-PI therapy for adults with severe AATD and emphysema when blood testing confirms significantly reduced alpha1-proteinase inhibitor levels and long-term augmentation therapy is needed to slow progression of lung disease, typically under specialist pulmonology care.
DIET & LIFESTYLE SUPPORT
A1-PI therapy works best alongside lifestyle changes that protect both the lungs and the liver. Smoking cessation, pulmonary rehabilitation, vaccination, and a liver-friendly diet all support long-term health for people with AATD.
Quitting smoking and avoiding dust, chemical fumes, and other respiratory irritants is essential for anyone with AATD, since these exposures speed up lung tissue damage.
Pulmonary rehabilitation, regular exercise as tolerated, and vaccination against influenza and pneumococcal disease help reduce infection risk and preserve lung function alongside A1-PI therapy.
Because AATD can also affect the liver, a liver-friendly diet and regular monitoring support liver health even though A1-PI therapy itself is directed at the lungs.
A nutrition bar designed for liver health can be a simple, consistent way to help meet daily energy and protein goals alongside A1-PI therapy.
Explore Liver Health Nutrition Bars
A1-PI THERAPY AND LIVER DISEASE
A1-PI augmentation therapy was developed to protect the lungs, not the liver. In AATD, the abnormal Z protein misfolds and accumulates inside liver cells instead of being secreted into the blood — this buildup is what damages the liver, and it happens whether or not a person receives A1-PI infusions. A1-PI therapy replaces the AAT protein missing from the bloodstream, which protects the lungs from neutrophil elastase, but it does not correct or remove the abnormal Z protein that has already built up inside liver cells. Because replacing circulating AAT protein does not clear this intracellular accumulation, A1-PI therapy cannot reverse or prevent AATD-related liver disease.
Because of this, AATD-related liver disease is managed separately from lung-focused A1-PI therapy. People with AATD who have liver involvement are followed with regular liver enzyme testing and liver health checks, and any related liver condition, such as cirrhosis, is treated on its own terms. Anyone with AATD who smokes should quit, since smoking accelerates lung damage, and everyone with AATD — whether or not they are on A1-PI therapy — benefits from routine monitoring of both lung and liver health.
TREATMENT MONITORING
Regular monitoring helps your healthcare team track both your lung function and your liver health while you are on A1-PI therapy. Follow-up care typically includes pulmonology assessment alongside separate liver-focused blood tests and imaging.
Regular monitoring of lung function, infusion-related reactions, and overall clinical response is recommended, with periodic reassessment by a pulmonology specialist.
Because A1-PI therapy does not treat the liver, people with AATD benefit from separate liver function tests to track liver enzymes and flag changes early.
Genetic testing and blood testing for alpha-1 antitrypsin levels help confirm an AATD diagnosis and guide whether A1-PI therapy is appropriate for lung disease.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
A1-PI therapy treats adults with severe Alpha-1 Antitrypsin Deficiency (AATD) and clinically significant emphysema. It is a plasma-derived medication — available as Prolastin-C, Glassia, Aralast NP, or Zemaira — that replaces the missing alpha1-proteinase inhibitor protein to help protect lung tissue from ongoing damage. It is not used to treat AATD-related liver disease, since it targets circulating protein levels rather than the liver injury caused by abnormal protein buildup inside liver cells. Talk with your specialist about whether this therapy fits your care plan.
A1-PI therapy works by replacing the deficient alpha1-proteinase inhibitor protein in the bloodstream. This protein inhibits neutrophil elastase, an enzyme that damages lung tissue during inflammation, helping protect alveolar structures and slow the decline in lung function seen in AATD. The therapy does not correct the buildup of abnormal AAT protein inside liver cells, so it has no effect on AATD-related liver injury. Ask your healthcare provider how this mechanism applies to your specific diagnosis and treatment goals.
Adults with severe Alpha-1 Antitrypsin Deficiency and clinically significant emphysema, confirmed by blood testing showing significantly reduced alpha1-proteinase inhibitor levels, typically qualify for A1-PI therapy. Candidates generally need long-term augmentation therapy to slow lung disease progression and are usually under specialist pulmonology care. Eligibility depends on your specific diagnosis, lung function, and overall health history. Only a qualified healthcare provider can determine whether this therapy is appropriate for you, so discuss your test results and symptoms with your specialist before starting treatment.
No, A1-PI therapy does not treat AATD-related liver disease. Although Alpha-1 Antitrypsin Deficiency can damage both the lungs and the liver, this augmentation therapy replaces circulating AAT protein to protect the lungs only. It does not clear the abnormal Z protein that accumulates inside liver cells and causes liver injury. People with AATD-related liver disease need separate monitoring and management from a liver specialist, including regular liver enzyme testing. Talk with your healthcare provider about a monitoring plan that addresses both your lung and liver health.
The most commonly reported side effects of A1-PI therapy include headache, fatigue, dizziness, upper respiratory tract infections, and infusion-related reactions such as fever, chills, or discomfort during or after treatment. Most reactions are mild, but your healthcare provider will monitor you closely during each infusion and can adjust the infusion rate or provide supportive care if needed. Report any new or worsening symptoms to your care team promptly. Discuss your full health history with your provider so they can watch for reactions specific to your situation.
Quitting smoking is the most important lifestyle change for anyone with Alpha-1 Antitrypsin Deficiency, since smoking speeds up lung damage regardless of A1-PI therapy. Pulmonary rehabilitation, regular exercise as tolerated, avoiding respiratory irritants, and vaccination against influenza and pneumococcal disease all help preserve lung function. A liver-friendly diet and regular liver monitoring remain important too, since A1-PI therapy does not address liver-related risk. Ask your healthcare provider or a registered dietitian to help build a plan tailored to your needs.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
